Cell Therapy News Volume 22.24 | Jul 5 2021

    By
    Justin.choi
    -
    0
    57







    2021-07-05 | CTN 22.24


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.24 – 5 July, 2021
    TOP STORY

    Microbial Short-Chain Fatty Acids Modulate CD8+ T Cell Responses and Improve Adoptive Immunotherapy for Cancer

    Researchers showed that in vitro treatment of cytotoxic T lymphocytes and CAR T cells with pentanoate and butyrate increased the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity.
    [Nature Communications]

    Abstract
    The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.
    PUBLICATIONSRanked by the impact factor of the journal

    Targeted Cell Therapy for Partial-Thickness Cartilage Defects Using Membrane Modified Mesenchymal Stem Cells by Transglutaminase 2

    By modifying a functional polypeptide on the mesenchymal stem cell plasma membrane and exploiting the high expression of transglutaminase 2 in the regions of injured cartilage, the authors achieved targeted recognition and capture of modified mesenchymal stem cells by injured articular chondrocytes
    [Biomaterials]

    Full Article

    Sodium Alginate/Collagen/Stromal Cell-Derived Factor-1 Neural Scaffold Loaded with BMSCs Promotes Neurological Function Recovery after Traumatic Brain Injury

    Investigators synthesized a sodium alginate/collagen type I/stromal cell-derived factor-1(SDF-1) hydrogel and investigated whether the SA/Col/SDF-1 hydrogel loaded with bone marrow-derived mesenchymal stem cells had therapeutic effects on a traumatic brain injury model.
    [Acta Biomaterialia]

    AbstractGraphical Abstract

    Lenalidomide before and after Autologous Stem Cell Transplantation for Transplant-Eligible Patients of All Ages in the Randomized, Phase III, Myeloma XI Trial

    Patients with newly diagnosed multiple myeloma were randomized to induction therapy with cyclophosphamide, thalidomide, and dexamethasone or cyclophosphamide, lenalidomide, and dexamethasone.
    [Haematologica]

    Full Article

    Systematic Comparison of Promoter, DNA Vector, and Cationic Carrier for Efficient Transfection of Human Mesenchymal Stem Cells from Multiple Donors and Tissue Sources

    The authors investigated two promoters, four DNA vectors, two cationic carriers, and four donors of human mesenchymal stem cells from two tissues for efficient hMSC transfection.
    [Molecular Therapy-Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    Hypoproliferative Human Neural Progenitor Cell Xenografts Survived Extendedly in the Brain of Immunocompetent Rats

    Neuron-restricted neural progenitor cells were derived from human embryonic stem cells, propagated for different passages, and then transplanted into the brain of immunocompetent rats without immunosuppressants.
    [Stem Cell Research & Therapy]

    Full Article

    Reconstructing Single-Cell Karyotype Alterations in Colorectal Cancer Identifies Punctuated and Gradual Diversification Patterns

    Using patient-derived colorectal cancer organoids and fresh tumor biopsies, the investigators demonstrated that karyotype alterations of varying complexity were prevalent and could arise within a few cell generations.
    [Nature Genetics]

    Full Article

    Interpretable Systems Biomarkers Predict Response to Immune-Checkpoint Inhibitors

    Scientists used interpretable machine learning to extract from these structured data mechanistic biomarkers of antitumor immune responses that effectively predicted patients’ response to immune checkpoint blockade.
    [Patterns]

    AbstractPress Release

    Reductions in AFP and PIVKA-II Can Predict the Efficiency of Anti-PD-1 Immunotherapy in HCC Patients

    The authors investigated the prognostic role of AFP and PIVKA-II in hepatocellular carcinoma patients receiving anti-PD-1 immunotherapy.
    [BMC Cancer]

    Full Article
    Download the cell separation e-book, a practical guide on everything you need to know about cell isolation techniques.
    REVIEWS

    Advances in Stem Cell Research for the Treatment of Primary Hypogonadism

    Over the past two decades, substantial advances have been made in the identification of Leydig cell sources for use in transplantation surgery, including the artificial induction of Leydig-like cells from different types of stem cells, for example, stem Leydig cells, mesenchymal stem cells, and pluripotent stem cells.
    [Nature Reviews Urology]

    Abstract

    Optimizing the Treatment of Acute Lymphoblastic Leukemia in Younger and Older Adults: New Drugs and Evolving Paradigms

    With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of acute lymphoblastic leukemia in both younger and older adults has substantially improved.
    [Leukemia]

    Abstract

    Immunological Considerations and Challenges for Regenerative Cellular Therapies

    Scientists describe the role of the host innate and adaptive immune responses as triggers of allogeneic graft rejection. They discuss how the immune response is determined by the cellular therapy.
    [Communications Biology]

    Full Article
    INDUSTRY AND POLICY NEWS

    AAV Vector Gene Therapy, Now in Phase I/II Trials, Targets Methylmalonic Acidemia

    At Monroe Carell Jr. Children’s Hospital at Vanderbilt, the first child with methylmalonic acidemia has been treated with hLB-001 gene therapy, which uses an adeno-associated virus (AAV) vector to correct a genetic defect.
    [Vanderbilt University]

    Press Release

    Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma

    Kite, a Gilead Company announced top-line results from the primary analysis of ZUMA-7, a randomized Phase III global, multicenter study showing superiority of Yescarta® compared to standard of care in second-line relapsed or refractory large B-cell lymphoma.
    [Kite]

    Press Release
    FEATURED EVENT

    GammaDelta T Therapies Summit

    July 27 – 29, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Cell Therapies

    The Westmead Institute for Medical Research – Sydney, Australia

    Editor – Nature Materials

    Springer Nature – Multiple Locations

    Chief Scientific Officer – Fibroblasts and Stem Cells

    FibroBiologics – Houston, Texas, United States

    Assistant Professor – Tissue Assembly, Physiology, and Engineering

    University of Basel – Basel, Switzerland

    Postdoctoral Fellow – Cancer Pathogenesis

    Institute of Oncology Research – Bellinzona, Switzerland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter